Please assess the completion status of the following clinical trial:

Trial Title: Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed prostate cancer at high-risk for recurrence within the past 180 days as determined by 1 of the following combinations (risk groups):~  * Gleason score ≥ 9, prostate-specific antigen (PSA) ≤ 150 ng/mL, and any T stage~ * Gleason score 8, PSA \< 20 ng/mL, and stage ≥ T2~ * Gleason score 8, PSA 20-150 ng/mL, and any T stage~ * Gleason score 7, PSA 20-150 ng/mL, and any T stage~* Clinically negative lymph nodes by imaging (pelvic CT scan or pelvic MRI), nodal sampling, or dissection within 90 days prior to study entry~  * Equivocal or questionable lymph nodes ≤ 1.5 cm by imaging allowed~ * Positive lymph nodes by capromab pendetide (ProstaScint\^®) scan with a corresponding lymph node ≤ 1.5 cm by CT scan or MRI allowed~* PSA ≤ 150 ng/mL~  * Cannot have been obtained during any of the following time points:~    * 10-day period after prostate biopsy~   * After initiation of hormonal therapy~   * Within 30 days after discontinuation of finasteride~   * Within 90 days after discontinuation of dutasteride~* No distant metastases by physical exam and bone scan~  * Equivocal bone scan findings allowed if plain films are negative~PATIENT CHARACTERISTICS:~* Zubrod performance status 0-1~* Platelet count ≥ 100,000/mm\^3~* Absolute neutrophil count ≥ 1,800/mm\^3~* Hemoglobin ≥ 8 g/dL (transfusion or other intervention allowed)~* Alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤ 1.5 times upper limit of normal (ULN)~* Alkaline phosphatase ≤ 2.5 times ULN~* Bilirubin ≤ 1.5 times ULN~* Fertile patients must use effective contraception during and for at least 3 months after completion of study treatment~* No prior invasive malignancy, except nonmelanomatous skin cancer or other malignancy, unless disease-free for ≥ 3 years (e.g., carcinoma in situ of the oral cavity or bladder are allowed)~* No unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months~* No transmural myocardial infarction within the past 6 months~* No acute bacterial or fungal infection requiring intravenous antibiotics~* No AIDS~* No prior allergic reaction to any study drugs or other drugs formulated with polysorbate 80~* No existing peripheral neuropathy ≥ grade 2~PRIOR CONCURRENT THERAPY:~* At least 60 days since prior 5-alpha reductase inhibitor (e.g., finasteride) for prostatic hypertrophy~* At least 90 days since prior testosterone~* Prior pharmacologic androgen ablation for prostate cancer allowed provided androgen ablation was initiated no more than 50 days prior to study entry~* No prior radical prostatectomy, cryosurgery for prostate cancer, or bilateral orchiectomy~* No prior systemic chemotherapy for prostate cancer~  * Prior chemotherapy for a different cancer is allowed~* No prior radiotherapy, including brachytherapy, to the region of prostate cancer that would result in overlap of radiotherapy fields~* Intensity modulated radiotherapy allowed

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Androgen suppression + Radiation Therapy (Type: ACTIVE_COMPARATOR): Androgen suppression (AS; LHRH agonist and oral antiandrogen) for 8 weeks followed by radiation therapy and concurrent AS. LHRH continues for 24 months after initiation of any treatment, oral antiandrogen discontinues at the end of radiation therapy (RT).
- Androgen suppression + Radiation Therapy + Chemotherapy (Type: EXPERIMENTAL): Androgen suppression (AS; LHRH agonist and oral antiandrogen) for 8 weeks followed by radiation therapy and concurrent AS. LHRH continues for 24 months after initiation of any treatment, oral antiandrogen discontinues at the end of RT. Following completion of RT, 6 cycles of docetaxel (premedicated with dexamethasone) and prednisone are delivered concurrently with androgen suppression.

Based on this trial design, predict the completion outcome and termination type (if applicable).